Advertisement

Experimental Brain Research

, Volume 88, Issue 2, pp 277–282 | Cite as

Comparative analysis of seizures induced by intracerebroventricular administration of NMDA, kainate and quisqualate in mice

  • C. Mathis
  • A. Ungerer
Regular Papers

Summary

The dose-related time course and occurrence of different seizure subtypes was examined in mice after i.c.v. administration of N-methyl-D-aspartate (NMDA), kainate (KA) or quisqualate (QA). At doses of 0.2 to 1 nmol, NMDA dose-dependently induced a single clonic-tonic seizure. Low doses (0.1 to 0.3 nmol) of KA induced only mild myoclonus and whole body clonus, which were dose-dependently replaced by short-delay clonic-tonic seizures at higher doses (0.4 to 1.2 nmol). In contrast, mice treated with 13 to 32 nmol of QA exhibited either mild myoclonus or whole body clonus as well as clonic-tonic seizures. Clonic-tonic seizures induced by NMDA or KA appeared at shorter latencies than those induced by QA, whereas whole body clonus induced by KA or QA appeared with long onset latencies. These results clearly show that i.c.v. administration of NMDA, KA and QA produces different patterns of seizures in mice. This study confirms that NMDA, KA and QA induce convulsions through different underlying mechanisms and suggests that different anatomical pathways are involved in these models.

Key words

Seizures Excitatory amino acids Animal models of epilepsy Mouse 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Avoli M, Olivier A (1989) Electrophysiological properties and synaptic responses in the deep layers of the human epileptogenic neocortex in vitro. J Neurophysiol 61: 589–606PubMedGoogle Scholar
  2. Ben-Ari Y (1985) Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 14: 375–403CrossRefPubMedGoogle Scholar
  3. Ben-Ari Y, Tremblay E, Riche D, Ghilini G, Naquet R (1981) Electrographic, clinical and pathological alterations following systemic administration of kainic acid, bicuculline or pentetrazole: metabolic mapping using the deoxyglucose method with special reference to the pathology of epilepsy. Neuroscience 6: 1361–1391CrossRefPubMedGoogle Scholar
  4. Browning RA, Nelson DK (1986) Modification of electroshock and pentylenetetrazol seizure patterns in rats after precollicular transections. Exp Neurol 93: 546–556CrossRefPubMedGoogle Scholar
  5. Browning R, Wang C, Lanker ML, Jobe PC (1990) Electroshock-and pentylenetetrazol-induced seizures in genetically epilepsyprone rats (GEPRs): differences in threshold and pattern. Epilepsy Res 6: 1–11CrossRefPubMedGoogle Scholar
  6. Chapman AG, Hart GP, Meldrum BS, Turski L, Watkins JC (1985) Anticonvulsant activity of two novel piperazine derivatives with potent kainate antagonist activity. Neurosci Lett 55: 325–330CrossRefPubMedGoogle Scholar
  7. Collins RL (1972) Audiogenic seizures. In: Purpura DP, Penry JK, Tower D, Woodbury DM, Walter R (eds) Experimental models of epilepsy- a manual for the laboratory worker. Raven Press, New York, pp 347–372Google Scholar
  8. Croucher MJ, Collins JF, Meldrum BS (1982) Anticonvulsant action of excitatory amino acid antagonists. Science 216: 899–901Google Scholar
  9. Czuczwar SJ, Meldrum BS (1982) Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. Eur J Pharmacol 83: 335–338CrossRefPubMedGoogle Scholar
  10. De Sarro G, Meldrum BS, Reavill C (1985) Anticonvulsant action of 2-amino-7-phosphonoheptanoic acid in the substantia nigra. Eur J Pharmacol 106: 175–179CrossRefGoogle Scholar
  11. Engstrom FL, Woodbury DM (1988) Seizure susceptibility in DBA and C57 mice: the effects of various convulsants. Epilepsia 29: 389–395PubMedGoogle Scholar
  12. French ED, Aldinio C, Schwarcz R (1982) Intrahippocampal kainic acid, seizures and local neuronal degeneration: relationships assessed in unanesthetized rats. Neuroscience 7: 2525–2536CrossRefPubMedGoogle Scholar
  13. Gale K (1988) Progression and generalization of seizure discharge: anatomical and neurochemical substrates. Epilepsia 29: S15-S34Google Scholar
  14. Klockgether T, Turski L, Schwarz M, Sontag K-H, Lehmann J (1988) Paradoxical convulsant action of a novel non-competitive N-methyl-D-aspartate (NMDA) antagonist, tiletamine. Brain Res 461: 343–348CrossRefPubMedGoogle Scholar
  15. Koek W, Colpaert FC (1990) Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects. J Pharmacol Exp Ther 252: 343–357Google Scholar
  16. Kosobud AE, Crabbe JC (1990) Genetic correlations among inbred strain sensitivities to convulsions induced by 9 convulsant drugs. Brain Res 526: 8–16CrossRefPubMedGoogle Scholar
  17. Leander JD, Lawson RR, Orstein PL, Zimmerman DM (1988) N-methyl-D-aspartic acid-induced lethality in mice: selective antagonism by phencyclidine-like drugs. Brain Res 448: 115–120CrossRefPubMedGoogle Scholar
  18. Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy DE, Steel DJ, Williams M, Cheney DL, Wood PL (1988) CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther 246: 65–75PubMedGoogle Scholar
  19. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effects experiments. J Pharmacol Exp Ther 96: 99–113Google Scholar
  20. London ED, Coyle JT (1979) Specific binding of [3H]kainic acid to receptor sites in rat brain. Mol Pharmacol 15: 492–505PubMedGoogle Scholar
  21. Löscher W, Nolting B, Hönack D (1988) Evaluation of CPP, a selective NMDA antagonist, in various models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital. Eur J Pharmacol 152: 9–17CrossRefPubMedGoogle Scholar
  22. Mathis C, De Barry J, Ungerer A (1990) NMDA antagonist properties of γ-L-glutamyl-L-aspartate demonstrated on chemically induced seizures in mice. Eur J Pharmacol 185: 53–59CrossRefPubMedGoogle Scholar
  23. Meldrum BS (1985) Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin Sci 68: 113–122PubMedGoogle Scholar
  24. Moreau J-L, Pieri L, Prud'hon B (1989) Convulsions induced by centrally administered NMDA in mice: effects of NMDA antagonists, benzodiazepines, minor tranquilizers and anticonvulsants. Br J Pharmacol 98: 1050–1054PubMedGoogle Scholar
  25. Nadler JV (1981) Minireview: Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci 29: 2031–2042CrossRefPubMedGoogle Scholar
  26. Olney JW, Rhee V, Ho OL (1974) Kainic acid a powerful neurotoxic analogue of glutamate. Brain Res 77: 507–512CrossRefPubMedGoogle Scholar
  27. Schwarz SS, Freed WJ (1986) Inhibition of quisqualate-induced seizures by glutamic acid diethyl ester and antiepileptic drugs. J Neural Trans 67: 191–203CrossRefGoogle Scholar
  28. Sherwin A, Robitaille Y, Quesney F, Olivier A, Villemure J, Leblanc R, Feindel W, Andermann E, Gotman J, Andermann F, Ethier R, Kish S (1988) Excitatory amino acids are elevated in human epileptic cerebral cortex. Neurology 38: 920–923PubMedGoogle Scholar
  29. Slevin JT, Collins JF, Coyle JT (1983) Analogue interactions with the brain receptor labelled [3H]kainic acid. Brain Res 265: 169–172CrossRefPubMedGoogle Scholar
  30. Shinozaki H, Hirate K, Ishida M (1987) Modification of drug-induced tremor by systemic administration of kainic acid and quisqualic acid in mice. Neuropharmacology 26: 9–17CrossRefPubMedGoogle Scholar
  31. Turski L, Meldrum BS, Collins JF (1985) Anticonvulsant action ofβ-kainic acid in mice. Isβ-kainic acid an N-methyl-D-aspartate antagonist? Brain Res 336: 162–166Google Scholar
  32. Turski L, Klockgether T, Sontag K-H, Herrling PL, Watkins JC (1987) Muscle relaxant and anticonvulsant activity of 3-((±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid, a novel N-methyl-D-aspartate antagonist, in rodents. Neurosci Lett 73: 143–148CrossRefPubMedGoogle Scholar
  33. Worms P, Willigens MT, Lloyd KG (1981) The behavioral effects of systemically administrated kainic acid: a pharmacological analysis. Life Sci 29: 2215–2225CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • C. Mathis
    • 1
  • A. Ungerer
    • 1
  1. 1.Laboratoire de PsychophysiologieUniversité Louis PasteurStrasbourgFrance

Personalised recommendations